In parallel, by examining 5′-half-tRNA-type and 14-nt linear-type sgRNAs designed to target appropriate mRNAs such as the BCL2, CCND1, and IRF4 mRNAs for their ability to induce apoptosis in myeloma cells, potential sgRNA therapeutics would be expected to be found. This evidence concerns the gene BCL2 and plasma cell myeloma.